



Amplify Weight Loss Drug & Treatment ETF



THNR (Principal U.S. Listing Exchange: NYSE Arca)

Semi-Annual Shareholder Report | March 31, 2025

This semi-annual shareholder report contains important information about the Amplify Weight Loss Drug & Treatment ETF (the “Fund”) for the period of October 1, 2024, to March 31, 2025. You can find additional information about the Fund at <https://amplifyetfs.com/fund-documents/>. You can also request this information by contacting us at 855-267-3837.

WHAT WERE THE FUND COSTS FOR THE LAST SIX MONTHS? (based on a hypothetical \$10,000 investment)

Fund Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment*
Amplify Weight Loss Drug & Treatment ETF	\$27	0.59%

* Annualized

KEY FUND STATISTICS (as of March 31, 2025)


Net Assets	\$3,871,107
Number of Holdings	27
Portfolio Turnover	22%
30-Day SEC Yield	1.33%
30-Day SEC Yield Unsubsidized	1.33%

Visit <https://amplifyetfs.com/fund-documents/> for more recent performance information.

WHAT DID THE FUND INVEST IN? (as of March 31, 2025)*

Top Holdings	(%)
Eli Lilly & Co.	15.8%
Novo Nordisk AS	14.0%
First American Government Obligations Fund - Class X	13.9%
West Pharmaceutical Services, Inc.	5.1%
Chugai Pharmaceutical Co. Ltd.	5.1%
Thermo Fisher Scientific, Inc.	5.0%
Merck & Co., Inc.	4.8%
Amgen, Inc.	4.7%
Innovent Biologics, Inc.	4.7%
Pfizer, Inc.	4.7%

Sector Breakdown**



- Health Care (94.0%)
- Materials (3.4%)
- Cash & Other (2.6%)

* Percentages are stated as a percent of net assets.

** The Global Industry Classification Standard (“GICS®”) was developed by and/or is the exclusive property of MSCI, Inc. (“MSCI”) and Standard & Poor’s Financial Services LLC (“S&P”). GICS® is a service mark of MSCI and S&P and has been licensed for use by U.S. Bank Global Fund Services.

For additional information about the Fund; including its prospectus, financial information, holdings and proxy information, scan the QR code or visit <https://amplifyetfs.com/fund-documents/>.

HOUSEHOLDING

To reduce Fund expenses, only one copy of most shareholder documents may be mailed to shareholders with multiple accounts at the same address (Householding). If you would prefer that your Amplify Investments, LLC documents not be househanded, please contact Amplify Investments, LLC at 855-267-3837, or contact your financial intermediary. Your instructions will typically be effective within 30 days of receipt by Amplify Investments, LLC or your financial intermediary.